Roy G. Geronemus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roy G. Geronemus has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Jordan V. Wang
Laser & Skin Surgery Center of New York, New York, New York
2 shared publications Aashish Didwania
Department of Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
1 shared publication- Andrew C. Krakowski
St. Luke’s University Health Network
1 shared publication Anetta Reszko
New York Presbyterian-Weill Cornell Medical Center, New York, New York, USA
1 shared publication- Arielle Kauvar
New York Laser & Skin Care New York New York USA
1 shared publication - Bianca Y. Kang
Department of Dermatology Mayo Clinic Scottsdale Arizona USA
1 shared publication
Latest Publications
- Open Access
- 1 October 2022
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 158 (10) , 1193-1201
Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery
Importance: Laser-assisted drug delivery (LADD) is used for various medical and cosmetic applications. However, there is insufficient evidence-based guidance to assist clinicians performing LADD.Objective: To develop recommendations for the safe and effective use of LADD.Evidence Review: A systematic literature review of Cochrane Central Register of Controlled Trials, Embase, and MEDLINE was conducted in December 2019 to identify publications reporting research on LADD. A multidisciplinary panel was convened to draft recommendations informed by the systematic review; they were refined through 2 rounds of Delphi survey, 2 consensus meetings, and iterative review by all panelists until unanimous consensus was achieved.Findings: Of the 48 published studies of ablative fractional LADD that met inclusion criteria, 4 were cosmetic studies; 21, oncologic; and 23, medical (not cosmetic/oncologic), and 6 publications of nonablative fractional LADD were included at the request of the expert panel, producing a total of 54 studies. Thirty-four studies (63.0%) were deemed to have low risk of bias, 17 studies (31.5%) had moderate risk, and 3 (5.5%) had serious risk. The key findings that informed the guidelines developed by the expert panel were as follows: LADD is safe in adults and adolescents (≥12 years) with all Fitzpatrick skin types and in patients with immunosuppression; it is an effective treatment for actinic keratosis, cutaneous squamous cell carcinoma in situ, actinic cheilitis, hypertrophic scars, and keloids; it is useful for epidermal and dermal analgesia; drug delivery may be increased through the application of heat, pressure, or occlusion, or by using an aqueous drug solution; laser settings should be selected to ensure that channel diameter is greater than the delivered molecule; antibiotic prophylaxis is not recommended, except with impaired wound healing; antiviral prophylaxis is recommended when treating the face and genitalia; and antifungal prophylaxis is not recommended. The guideline’s 15 recommendations address 5 areas of LADD use: (I) indications and contraindications; (II) parameters to report; (III) optimization of drug delivery; (IV) safety considerations; and (V) prophylaxis for bacterial, viral, and fungal infections.Conclusions and Relevance: This systematic review and Delphi consensus approach culminated in an evidence-based clinical practice guideline for safe and effective use of LADD in a variety of applications. Future research will further improve our understanding of this novel treatment technique.
- 1 October 2022
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 158 (10) , 1193-1201
Open AccessEvidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery
Importance: Laser-assisted drug delivery (LADD) is used for various medical and cosmetic applications. However, there is insufficient evidence-based guidance to assist clinicians performing LADD.Objective: To develop recommendations for the safe and effective use of LADD.Evidence Review: A systematic literature review of Cochrane Central Register of Controlled Trials, Embase, and MEDLINE was conducted in December 2019 to identify publications reporting research on LADD. A multidisciplinary panel was convened to draft recommendations informed by the systematic review; they were refined through 2 rounds of Delphi survey, 2 consensus meetings, and iterative review by all panelists until unanimous consensus was achieved.Findings: Of the 48 published studies of ablative fractional LADD that met inclusion criteria, 4 were cosmetic studies; 21, oncologic; and 23, medical (not cosmetic/oncologic), and 6 publications of nonablative fractional LADD were included at the request of the expert panel, producing a total of 54 studies. Thirty-four studies (63.0%) were deemed to have low risk of bias, 17 studies (31.5%) had moderate risk, and 3 (5.5%) had serious risk. The key findings that informed the guidelines developed by the expert panel were as follows: LADD is safe in adults and adolescents (≥12 years) with all Fitzpatrick skin types and in patients with immunosuppression; it is an effective treatment for actinic keratosis, cutaneous squamous cell carcinoma in situ, actinic cheilitis, hypertrophic scars, and keloids; it is useful for epidermal and dermal analgesia; drug delivery may be increased through the application of heat, pressure, or occlusion, or by using an aqueous drug solution; laser settings should be selected to ensure that channel diameter is greater than the delivered molecule; antibiotic prophylaxis is not recommended, except with impaired wound healing; antiviral prophylaxis is recommended when treating the face and genitalia; and antifungal prophylaxis is not recommended. The guideline’s 15 recommendations address 5 areas of LADD use: (I) indications and contraindications; (II) parameters to report; (III) optimization of drug delivery; (IV) safety considerations; and (V) prophylaxis for bacterial, viral, and fungal infections.Conclusions and Relevance: This systematic review and Delphi consensus approach culminated in an evidence-based clinical practice guideline for safe and effective use of LADD in a variety of applications. Future research will further improve our understanding of this novel treatment technique.
- 20 September 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (12) , 6691-6694
Diversity trends in the leadership of the American Society for Laser Medicine And Surgery, 1996–2021
Objectives: To evaluate the temporal trends in diversity within the ASLMS board of directions from 1996 to 2021. Materials and Methods: A list of Board of Directors from 1996 to 2021 was obtained from ASLMS headquarters. Using a composite of publicly available resources through internet searches, board director characteristics, such as age, gender, race/ethnicity, terminal degrees, specialties/field of expertise, and current full-time affiliations, were recorded. Results: One hundred forty-six unique individuals held 628 ALSMS board member positions from the years 1996-2021. The median age of the board members started with a median age of 43.0 years old in 1996 to 54.5 years old in 2021. The age spread between first and third quartiles (interquartile range) in each year in more recent years (2014-2019) was 17.0, 20.0, 18.8, 18.8, 18.0, and 15.3 years, respectively. Female representation started with 10.5% in 1996 to 30.8% in 2021. Diversity, by racial/ethnicity measures, has more representation of Asian (average across 1996-2010: 2.3% to 2010-2022: 19.0%) and Hispanic (average 1996-2010: 0.7% to 2010-2022: 4.4%) board members. No African American has held a position across these decades. MD holders (average 66.5%) and other degree holders (average 33.5%) have been relatively consistent across all years observed. From 2016 to 2021, dermatologists held board member seats at an average rate of 56.5% across these years, while prior, from 1996 to 2015, 67.3% of board member seats on average were held by members of other expertises. Most board members have full-time affiliations in private practice across most years observed (average 43.7% across all years observed). Conclusion: After analyzing the diversity trends across board members in ASLMS across 1996-2020, we have noticed overall trends of increased diversity over time that reflect a greater chance of bringing in new ideas and experiences to grow ASLMS. Although the leadership of ASLMS has become significantly more diverse over time, there remain opportunities to increase diversity further, including women, underrepresented ethnic minorities, and other experts of specialties other than dermatology.
- 20 September 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (12) , 6691-6694
Diversity trends in the leadership of the American Society for Laser Medicine And Surgery, 1996–2021
Objectives: To evaluate the temporal trends in diversity within the ASLMS board of directions from 1996 to 2021. Materials and Methods: A list of Board of Directors from 1996 to 2021 was obtained from ASLMS headquarters. Using a composite of publicly available resources through internet searches, board director characteristics, such as age, gender, race/ethnicity, terminal degrees, specialties/field of expertise, and current full-time affiliations, were recorded. Results: One hundred forty-six unique individuals held 628 ALSMS board member positions from the years 1996-2021. The median age of the board members started with a median age of 43.0 years old in 1996 to 54.5 years old in 2021. The age spread between first and third quartiles (interquartile range) in each year in more recent years (2014-2019) was 17.0, 20.0, 18.8, 18.8, 18.0, and 15.3 years, respectively. Female representation started with 10.5% in 1996 to 30.8% in 2021. Diversity, by racial/ethnicity measures, has more representation of Asian (average across 1996-2010: 2.3% to 2010-2022: 19.0%) and Hispanic (average 1996-2010: 0.7% to 2010-2022: 4.4%) board members. No African American has held a position across these decades. MD holders (average 66.5%) and other degree holders (average 33.5%) have been relatively consistent across all years observed. From 2016 to 2021, dermatologists held board member seats at an average rate of 56.5% across these years, while prior, from 1996 to 2015, 67.3% of board member seats on average were held by members of other expertises. Most board members have full-time affiliations in private practice across most years observed (average 43.7% across all years observed). Conclusion: After analyzing the diversity trends across board members in ASLMS across 1996-2020, we have noticed overall trends of increased diversity over time that reflect a greater chance of bringing in new ideas and experiences to grow ASLMS. Although the leadership of ASLMS has become significantly more diverse over time, there remain opportunities to increase diversity further, including women, underrepresented ethnic minorities, and other experts of specialties other than dermatology.
- 16 February 2022
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 48 (3) , 320-321
Commentary on “Causes of Injury and Litigation in Cutaneous Laser Surgery: An Update From 2012 to 2020”
An abstract is unavailable. This article is available as a PDF only.
- 16 February 2022
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 48 (3) , 320-321
Commentary on “Causes of Injury and Litigation in Cutaneous Laser Surgery: An Update From 2012 to 2020”
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 29 October 2021
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery - Global Open
- Vol. 9 (10) , e3905
Cytrellis: A Novel Microcoring Technology for Scarless Skin Removal: Summary of Three Prospective Clinical Trials
Background: We introduce an innovative and novel technology that achieves scarless skin removal without the use of thermal energy. Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar. This method is advantageous compared to other fractional devices, given that it has the same benefits as energy-based devices (removal of skin cores without a scar), with the added value of immediate closure along the relaxed skin tension lines, with significantly less thermal energy. Methods: Three prospective clinical safety trials analyzing MCT treatment on abdominal and facial skin (short- and long-term) are described. Results: MCT treatment of human skin resulted in scarless skin removal that was well tolerated by patients. Healing occurred rapidly, with limited side effects. Skin area reduction (skin tightening) and increase in skin thickness were observed long term. Conclusions: MCT treatment of human skin is safe and well tolerated. Although further studies on efficacy are required to evaluate the full potential of MCT in skin rejuvenation, early findings such as skin tightening and increase in skin thickness are encouraging.
- 29 October 2021
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery - Global Open
- Vol. 9 (10) , e3905
Open AccessCytrellis: A Novel Microcoring Technology for Scarless Skin Removal: Summary of Three Prospective Clinical Trials
Background: We introduce an innovative and novel technology that achieves scarless skin removal without the use of thermal energy. Microcoring technology (MCT) uses a modified, hollow hypodermic needle to remove skin safely and without a scar. This method is advantageous compared to other fractional devices, given that it has the same benefits as energy-based devices (removal of skin cores without a scar), with the added value of immediate closure along the relaxed skin tension lines, with significantly less thermal energy. Methods: Three prospective clinical safety trials analyzing MCT treatment on abdominal and facial skin (short- and long-term) are described. Results: MCT treatment of human skin resulted in scarless skin removal that was well tolerated by patients. Healing occurred rapidly, with limited side effects. Skin area reduction (skin tightening) and increase in skin thickness were observed long term. Conclusions: MCT treatment of human skin is safe and well tolerated. Although further studies on efficacy are required to evaluate the full potential of MCT in skin rejuvenation, early findings such as skin tightening and increase in skin thickness are encouraging.
- 21 October 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (12) , 3205-3207
Seasonality of procedures in dermatology: Insights for practice management
Recent demand for minimally and non‐invasive cosmetic procedures has been rising. According to the American Society for Dermatologic Surgery (ASDS), the numbers of injectable neuromodulator and soft‐tissue filler procedures have increased by 42% and 78%, respectively, since 2012.1 Similarly, laser, light, and energy‐based treatments have increased by 74%. Although it has been anecdotally reported that the popularity of dermatologic procedures may peak during specific times of the year, available data on consumer behavior is limited.2,3 Understanding seasonal trends can offer insights to better forecast patient demand and optimize practice management. In order to fill this gap in the literature, we performed a temporal analysis of various procedures in a busy dermatology clinic.
- 21 October 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (12) , 3205-3207
Seasonality of procedures in dermatology: Insights for practice management
Recent demand for minimally and non‐invasive cosmetic procedures has been rising. According to the American Society for Dermatologic Surgery (ASDS), the numbers of injectable neuromodulator and soft‐tissue filler procedures have increased by 42% and 78%, respectively, since 2012.1 Similarly, laser, light, and energy‐based treatments have increased by 74%. Although it has been anecdotally reported that the popularity of dermatologic procedures may peak during specific times of the year, available data on consumer behavior is limited.2,3 Understanding seasonal trends can offer insights to better forecast patient demand and optimize practice management. In order to fill this gap in the literature, we performed a temporal analysis of various procedures in a busy dermatology clinic.
- Open Access
- 1 August 2015
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 73 (2) , e71
Topical rapamycin combined with pulsed dye laser (PDL) in the treatment of capillary vascular malformations—Anatomical differences in response to PDL are relevant to interpretation of study results
- 1 August 2015
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 73 (2) , e71
Open AccessTopical rapamycin combined with pulsed dye laser (PDL) in the treatment of capillary vascular malformations—Anatomical differences in response to PDL are relevant to interpretation of study results
- 14 July 2008
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 34 (10) , 1423-1426
Reversal of Laser-Induced Hypopigmentation with a Narrow-Band UV-B Light Source in a Patient with Skin Type VI
- 14 July 2008
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 34 (10) , 1423-1426
Reversal of Laser-Induced Hypopigmentation with a Narrow-Band UV-B Light Source in a Patient with Skin Type VI
- 20 March 1993
- Published by Wiley in Pediatric Dermatology
- Vol. 10 (1) , 71-76
Supraumbilical Midabdominal Raphe, Sternal Atresia, and Hemangioma in an Infant: Response of Hemangioma to Laser and Interferon Alfa‐2a
We cared for an Infant girl with the clinical constellation of supraumbllical midabdomlnal raphe, sternal atresia, and cutaneous facial and upper trunk hemangioma. This is the first report of this clinical association in the dermatologic literature. The vascular component of the disorder responded to fiashlamp‐pumped pulsed dye laser therapy and to systemic Interferon alfa‐2a (Roferon‐A).
- 20 March 1993
- Published by Wiley in Pediatric Dermatology
- Vol. 10 (1) , 71-76
Supraumbilical Midabdominal Raphe, Sternal Atresia, and Hemangioma in an Infant: Response of Hemangioma to Laser and Interferon Alfa‐2a
We cared for an Infant girl with the clinical constellation of supraumbllical midabdomlnal raphe, sternal atresia, and cutaneous facial and upper trunk hemangioma. This is the first report of this clinical association in the dermatologic literature. The vascular component of the disorder responded to fiashlamp‐pumped pulsed dye laser therapy and to systemic Interferon alfa‐2a (Roferon‐A).